高级别浆液性卵巢癌中FRα、TROP2与HER2的表达及其临床病理相关性
该回顾性研究分析193例原发性高级别浆液性卵巢癌(HGSOC)患者,采用免疫组化评估FRα、TROP2和HER2表达,并按HRD状态分层。结果显示FRα和TROP2高表达分别占51.8%和24.9%,HER2超低表达占25.4%,HRD阳性占66.3%。HRD阳性为独立有利预后因素,TROP2高表达为独立不良预后因素。
要点
- HGSOC中FRα和TROP2高表达常见,HER2超低表达约占四分之一。
- HRD阳性是独立有利预后因素,TROP2高表达是独立不良预后因素。
- 整合HRD状态与ADC靶点表达谱可能改善患者分层。
核心结论
- ADC靶点在HGSOC不同亚组中呈现不同表达谱。
- HRD状态与TROP2表达均为无进展生存期的独立预后因素。
- FRα和HER2虽无独立预后意义,仍是靶向治疗的 promising 候选。
研究设计与样本
- 回顾性分析193例原发性高级别浆液性卵巢癌患者。
- 采用免疫组化评估FRα、TROP2和HER2表达。
- HRD状态由致病性BRCA1/2突变和/或基因组瘢痕评分(GSS)≥45定义。
- 采用Kaplan-Meier分析、单变量Cox回归及多变量Cox回归评估生存结局。
主要发现
- FRα高表达占51.8%,TROP2高表达占24.9%,HER2超低表达占25.4%。
- HRD阳性肿瘤占66.3%。
- TROP2高表达与晚期FIGO分期显著相关(P = 0.027)。
- HER2表达在BRCA突变肿瘤中过度代表(P = 0.020)。
- 三重共表达罕见,仅占7.8%。
关键数值与推荐
- 多变量Cox回归显示HRD阳性为独立有利预后因素。
- 多变量Cox回归显示TROP2高表达为独立不良预后因素。
临床怎么用
- 可考虑将HRD状态与ADC靶点表达谱整合用于患者分层。
- TROP2高表达提示不良预后,或可辅助风险评价。
- FRα和HER2表达虽无独立预后意义,仍可作为靶向治疗候选标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To comprehensively characterize the expression, clinicopathological landscape, and potential prognostic relevance of actionable antibody-drug conjugate (ADC) targets (FRα, TROP2, HER2) in high-grade serous ovarian cancer (HGSOC), evaluated across molecular strata defined by homologous recombination deficiency (HRD) status. METHODS: We retrospectively analyzed 193 patients with primary HGSOC. FRα, TROP2, and HER2 expression were assessed by immunohistochemistry. HRD status was defined by the presence of pathogenic BRCA1/2 mutations and/or a Genomic Scar Score (GSS) ≥45. Clinicopathological correlations and survival outcomes were evaluated using Kaplan-Meier analysis, univariable Cox regression, and multivariable Cox regression models with adjustment for HRD status, PARP inhibitor exposure, and anti-angiogenic therapy. RESULTS: FRα and TROP2 were frequently expressed, with high expression observed in 51.8% and 24.9% of cases, respectively, whereas 25.4% exhibited ultra-low HER2 expression. HRD-positive tumors comprised 66.3% of the cohort. High TROP2 expression was significantly associated with advanced FIGO stage (P = 0.027), whereas HER2 expression was overrepresented in BRCA-mutated tumors (P = 0.020). Triple co-expression was rare, identified in only 7.8% of cases. Multivariable Cox regression analysis demonstrated that HRD positivity was an independent favorable prognostic factor, whereas high TROP2 expression was an independent adverse prognostic factor. CONCLUSION: ADC targets display distinct expression profiles across HGSOC subgroups. The present study confirms that both HRD status and TROP2 expression are independent prognostic factors for progression-free survival. Although FRα and HER2 do not demonstrate independent prognostic significance, they remain promising candidates for targeted therapy. The integration of HRD status with ADC target expression profiling may improve patient stratification and facilitate biomarker-driven therapeutic decision-making.
引用
- Zhao CL, Wang XP, Wei K, et al. Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian cancer: Expression and clinicopathological correlations. Gynecol Oncol. 2026. PMID: 42447657. doi:10.1016/j.ygyno.2026.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。